dm+d

Unassigned

New Medicines

Schizophrenia-associated acute psychosis

Information

New molecular entity
Karuna Therapeutics
Karuna Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Co-formulation of xanomeline (muscarinic acetylcholine receptor agonist) and trospium chloride (muscarinic antagonist). Selectively targets M1/M4 muscarinic receptors in the brain and blocks their activity in the peripheral tissues to improve tolerability
Schizophrenia affects around 1 in every 100 people over the course of their life.[1]
Schizophrenia-associated acute psychosis
Oral